Ocean Ring Technologies Competitors

We are the world’s leading Geo-data specialist, collecting and analysing comprehensive information about the Earth and the structures built upon it. Through integrated data acquisition, analysis and advice, we unlock insights from Geo-data to help our clients design, build and operate their assets in a safe, sustainable and efficient manner. Learn more about us: https://www.youtube.com/fugro https://www.facebook.com/fugro https://twitter.com/fugro https://www.instagram.com/fugro/

Our story began 50 years ago. Today, we are a global energy company leading the transition to a more sustainable future. We produce and deliver electricity to millions of families, businesses and communities worldwide, with a strong focus on renewable energy. More than 90% of the electricity we generate comes from clean sources, including wind, solar and hydroelectric power. Operating across Europe, North America, South America and Asia-Pacific, we are driving inclusive electrification through renewable generation, intelligent networks and digital solutions. Choosing Earth is our purpose and our ambition is clear: to deliver clean, secure and affordable energy while contributing to a more sustainable and resilient world. 50 years of bold choices and continuous innovation have shaped who we are today. If we achieved all this in our first 50 years, imagine what we will accomplish in the next 50. Welcome to the official LinkedIn page of the EDP Group.

Targeting Cancer. Transforming Therapies. Seagen is where revolutionary science meets transformative cancer therapy. Seagen is committed to advancing late-stage clinical trials and expanding the development of its portfolio both in and outside the U.S. to better the health of people with cancer. We are dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. We are focused on discovering, developing and commercializing a new generation of transformative cancer medicines and empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency. We are expanding indications for three already approved cancer medicines and a pipeline of more than five novel targeted therapies at various stages of preclinical and clinical testing designed to address significant unmet medical needs.